Past Podcast Episodes

Welcome to Part 2 of a special two-part RealTalk MS series highlighting conversations with past recipients of the Barancik Prize for Innovation in MS Research.

The Barancik Prize is awarded at the annual meeting of the Americas Committee for Treatment and Research in Multiple Sclerosis, a meeting better known as the ACTRIMS Forum. Several past Barancik Prize winners gathered at the 2023 ACTRIMS Forum to celebrate the 10th anniversary of the Barancik Prize, and I took that opportunity to chat with this remarkable group of MS research all-stars.

Dr. Katerina Akassoglou, Dr. Dwight Bergles, and Dr. Ruth Ann Marrie

Part 2 of Barancik Prize Conversations features the 2018, 2020, and 2022 Barancik Prize winners.

Dr. Katerina Akassolgou, of the Gladstone Institute of Neurological Disease, was awarded the Barancik Prize in 2018 for her work understanding the role of fibrin-related nerve damage in MS and designing potential therapies to prevent neurodegeneration.

Dr. Dwight Bergles, of Johns Hopkins University, received the Barancik Prize in 2020 in recognition of his pioneering research in understanding the brain cells involved in myelin repair.

Dr. Ruth Ann Marrie, of the University of Manitoba, is the 2022 recipient of the Barancik Prize in recognition of her groundbreaking contributions to our understanding of MS.

We have a lot to talk about! Are you ready for RealTalk MS??!

About the Barancik Prize Conversations :18

Dr. Katerina Akassoglou 2:03

Dr. Dwight Bergles 10:00

Dr. Ruth Ann Marrie 20:58

SHARE THIS EPISODE OF REALTALK MS

Just copy this link & paste it into your text or email: https://realtalkms.com/barancik2

ADD YOUR VOICE TO THE CONVERSATION

I've always thought about the RealTalk MS podcast as a conversation. And this is your opportunity to join the conversation by sharing your feedback, questions, and suggestions for topics that we can discuss in future podcast episodes. Please shoot me an email or call the RealTalk MS Listener Hotline and share your thoughts!

Email: jon@realtalkms.com
Phone: (310) 526-2283

And don't forget to join us in the RealTalk MS Facebook group!

LINKS

If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com

Join the RealTalk MS Facebook Group
https://facebook.com/groups/realtalkms

Download the RealTalk MS App for iOS Devices
https://itunes.apple.com/us/app/realtalk-ms/id1436917200

Download the RealTalk MS App for Android Devices
https://play.google.com/store/apps/details?id=tv.wizzard.android.realtalk

Give RealTalk MS a rating and review
http://www.realtalkms.com/review

Follow RealTalk MS on Twitter, @RealTalkMS_jon, and subscribe to our newsletter at our website, RealTalkMS.com.

RealTalk MS Bonus Episode: Barancik Prize Conversations — Part 2
Guests: Dr. Katerina Akassoglou, Dr. Dwight Bergles, and Dr. Ruth Ann Marrie

Tags: MS, MultipleSclerosis, MSResearch, MSSociety, RealTalkMS

Privacy Policy

Disclosing your MS to your employer is an important decision that can sometimes be tricky and can sometimes lead to unintended consequences. Joining me to discuss some of the things you want to be thinking about when it comes to disclosing your MS in the workplace is a Manager on the Benefits, Employment, and Insurance Team at the National MS Society, Christina Forster.

Christina Forster

We're also extending an invitation for you to spend a quick couple of minutes taking the RealTalk MS listener survey…and we're adding some motivation to that invitation by giving you an opportunity to win a $100 Amazon gift card.

And we're inviting you to get up close and personal with some of the most brilliant MS researchers in the world in Part 1 of our two-part special podcast series, Barancik Prize Conversations.

While we're talking about brilliant MS researchers, we're also revealing this year's recipient of the John Dystel Prize for MS Research.

We'll share some of the details surrounding the partial hold that the FDA has imposed on three different Phase 3 clinical trials for a new category of MS disease-modifying therapy.

We'll tell you about a small clinical trial that demonstrated the benefit of telerehabilitation in improving MS-related bladder problems.

And we'll tell you about an upcoming clinical trial for the first MS disease-modifying therapy to be formulated as a nasal spray.

We have a lot to talk about! Are you ready for RealTalk MS??!

Take the RealTalk MS listener survey…you might win a $100 Amazon gift card! :22

This Week: Disclosing your MS in the workplace 1:15

Don't miss Part 1 of our special series, Barancik Prize Conversations 2:07

And the winner of the John Dystel Prize for MS Research is… 4:05

The FDA has put a temporary hold on three Phase 3 clinical trials for a new category of MS disease-modifying therapy 5:42

STUDY: Telerehabilitation shown to be successful in managing MS-related bladder problems 8:39

Tiziana Life Scences announces Phase 2 clinical trial for Foralumab, the first MS disease-modifying therapy to be formulated as a nasal spray 12:05

Christina Forster reviews the things you'll want to consider when you're thinking about disclosing your MS to your employer 14:11

Share this episode 30:01

Please remember to take our listener survey! 30:21

SHARE THIS EPISODE OF REALTALK MS

Just copy this link & paste it into your text or email: https://realtalkms.com/292

ADD YOUR VOICE TO THE CONVERSATION

Email: jon@realtalkms.com
Phone: (310) 526-2283

And don't forget to join us in the RealTalk MS Facebook group!

LINKS

If your podcast app doesn't allow you to click on these links, you'll find them in the show notes in the RealTalk MS app or at www.RealTalkMS.com

Take the RealTalk MS Listener Survey
https://realtalkms.com/survey

RealTalk MS Special Podcast Series: Barancik Prize Conversations Part 1
https://realtalkms.com/barancik1

STUDY: Effects of Pelvic Floor Muscle Training Applied with Telerehabilitation in Patients with Multiple Sclerosis Having Lower Urinary Tract Symptoms: A Randomized Controlled Study
https://tandfonline.com/doi/abs/10.1080/07399332.2023.2190593